Literature DB >> 6120226

Changes in sensitivity to intrathecal norepinephrine and serotonin after 6-hydroxydopamine (6-OHDA), 5,6-dihydroxytryptamine (5,6-DHT) or repeated monoamine administration.

J R Howe, T L Yaksh.   

Abstract

The behaviorally defined analgesia evoked by direct application of norepinephrine (NE) or serotonin (5-HT) into the rat spinal subarachnoid space was assessed 1 to 28 days after respective intrathecal injection of 6-hydroxydopamine or 5,6-dihydroxytryptamine. These pretreatments effected supersensitivity to intrathecally administered NE and 5-HT, respectively, observable as early as 24 hr after neurotoxin-induced lesion. Dose-response curves for both NE or 5-HT, determined 7 days after pretreatment with their respective neurotoxins, were shifted significantly to the left as compared to controls. The onset of supersensitivity correlated well with the depletion of neurotransmitter levels in the spinal cord in the case of NE, but much correlation was not found for 5-HT. Whereas monoamine supersensitivity was undetectable 28 days postlesion, there was no significant recovery of spinal cord monoamine content at this time. Neurotoxin pretreatment was found to effect a significantly greater potentiation of NE- or 5-HT-induced analgesia than presynaptic reuptake blockade and elicited supersensitivity to agonists not readily taken up by presynaptic terminals, suggesting the involvement of postsynaptic components. Rats pretreated 7 days before with 5,6-dihydroxytryptamine exhibited some supersensitivity to intrathecal NE. Supersensitivity to 5-HT was not observed after 6-hydroxydopamine pretreatment. Rats made tachyphylactic to the antinociceptive effect of intrathecally injected NE displayed a complete lack of analgetic response to 5-HT. Similarly, rats tachyphylactic to 5-HT exhibited a subnormal analgetic response to NE. Combination pretreatment with both neurotoxins produced significant hyperalgesia as compared to yoked controls and to nociceptive thresholds determined before neurotoxin administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120226

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Descending serotonergic facilitation of spinal ERK activation and pain behavior.

Authors:  Camilla I Svensson; Thao K Tran; Bethany Fitzsimmons; Tony L Yaksh; Xiao-Ying Hua
Journal:  FEBS Lett       Date:  2006-11-14       Impact factor: 4.124

2.  Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic pain.

Authors:  S Ohnami; A Kato; K Ogawa; S Shinohara; H Ono; M Tanabe
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  5-HT agonist induced analgesia modulated by central but not peripheral noradrenaline depletion in rats.

Authors:  B G Minor; T Archer; C Post; G Jonsson; A K Mohammed
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

4.  Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance.

Authors:  B Milne; M Sutak; C M Cahill; K Jhamandas
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

5.  Differential effects of apomorphine on spinal reflex activity following 6-hydroxydopamine or long-term haloperidol pretreatment.

Authors:  T S Jensen; N J Christensen; D F Smith
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  Evidence for crosstolerance to the analgesic effects between morphine and selective alpha 2-adrenoceptor agonists.

Authors:  C Post; T Archer; B G Minor
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

7.  Supersensitivity to intrathecal 5-hydroxytryptamine, but not noradrenaline, following depletion of spinal 5-hydroxytryptamine by 5,7-dihydroxytryptamine administered into various sites.

Authors:  J Sawynok; A Reid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

8.  The spinal antinociceptive activity of the alpha 2-adrenoceptor agonist, xylazine in sheep.

Authors:  A E Kyles; A E Waterman; A Livingston
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

9.  Spinal 5-HT pathways and the antinociception induced by intramedullary clonidine in rats.

Authors:  M T Lin; C F Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

10.  Intrathecal noradrenaline restores 5-methoxy-N,N-dimethyltryptamine induced antinociception abolished by intrathecal 6-hydroxydopamine.

Authors:  B G Minor; M L Persson; C Post; G Jonsson; T Archer
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.